Evidence map›Paper›PMID 33503469›Full record

ArticleFood and chemical toxicology : an international journal published for the British Industrial Biological Research Association2021

Nicotinic cholinergic system and COVID-19: In silico identification of interactions between α7 nicotinic acetylcholine receptor and the cryptic epitopes of SARS-Co-V and SARS-CoV-2 Spike glycoproteins.

George Lagoumintzis, Christos T Chasapis, Nikolaos Alexandris, Dimitrios Kouretas, Socrates Tzartos, Elias Eliopoulos, Konstantinos Farsalinos, Konstantinos Poulas

Open access · greenAbstract read
In one paragraph

Article in Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 52 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Substances of abuse and their effect on SAR-CoV-2 pathogenesis.NeuroImmune pharmacology and therapeutics · 2023
    Review
  6. Observational
  7. Long COVID as a Tauopathy: Of "Brain Fog" and "Fusogen Storms".International journal of molecular sciences · 2023
    Review
  8. The controversial effect of smoking and nicotine in SARS-CoV-2 infection.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2023
    Review
  9. Review
  10. Article
  11. Cholinergic dysfunction in COVID-19: frantic search and hoping for the best.Naunyn-Schmiedeberg's archives of pharmacology · 2023
    Review
  12. Article
  13. Review
  14. An experimental test of the nicotinic hypothesis of COVID-19.Proceedings of the National Academy of Sciences of the United States of America · 2022
    Article
  15. New-onset myasthenia gravis after mRNA SARS-CoV-2 vaccination: a case series.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2022
    Article
  16. Article
  17. Article
  18. Inflammatory reflex disruption in COVID-19.Clinical & experimental neuroimmunology · 2022
    Review
  19. Smoking Status and Factors associated with COVID-19 In-Hospital Mortality among US Veterans.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2022
    Observational
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

George LagoumintzisLaboratory of Molecular Biology and Immunology, Department of Pharmacy, University of Patras, Panepistimiopolis, 26500, Rio-Patras, Greece.
Christos T ChasapisLaboratory of Molecular Biology and Immunology, Department of Pharmacy, University of Patras, Panepistimiopolis, 26500, Rio-Patras, Greece.
Nikolaos AlexandrisLaboratory of Molecular Biology and Immunology, Department of Pharmacy, University of Patras, Panepistimiopolis, 26500, Rio-Patras, Greece.
Dimitrios KouretasDepartment of Biochemistry and Biotechnology, Faculty of Animal Physiology -Toxicology, University of Thessaly, Larissa, Greece.
Socrates TzartosLaboratory of Molecular Biology and Immunology, Department of Pharmacy, University of Patras, Panepistimiopolis, 26500, Rio-Patras, Greece; Tzartos NeuroDiagnostics, 3, Eslin Street, Athens, 115 23, Greece.
Elias EliopoulosDepartment of Biotechnology, Laboratory of Genetics, Agricultural University of Athens, Iera Odos 75, 11855, Athens, Greece. Electronic address: eliop@aua.gr.
Konstantinos FarsalinosLaboratory of Molecular Biology and Immunology, Department of Pharmacy, University of Patras, Panepistimiopolis, 26500, Rio-Patras, Greece. Electronic address: kfarsalinos@gmail.com.
Konstantinos PoulasLaboratory of Molecular Biology and Immunology, Department of Pharmacy, University of Patras, Panepistimiopolis, 26500, Rio-Patras, Greece. Electronic address: kpoulas@upatras.gr.
University of Patras · GRAgricultural University of Athens · GRUniversity of Thessaly · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

SARS-CoV-2 is the coronavirus that originated in Wuhan in December 2019 and has spread globally. Studies have shown that smokers are less likely to be diagnosed with or be hospitalized for COVID-19 but, once hospitalized, have higher odds for an adverse outcome. We have previously presented the potential interaction between SARS-CoV-2 Spike glycoprotein and nicotinic acetylcholine receptors (nAChRs), due to a "toxin-like" epitope on the Spike glycoprotein, with homology to a sequence of a snake venom toxin. This epitope coincides with the well-described cryptic epitope for the human anti-SARS-CoV antibody CR3022. In this study, we present the molecular complexes of both SARS-CoV and SARS-CoV-2 Spike glycoproteins, at their open or closed conformations, with the model of the human α7 nAChR. We found that all studied protein complexes' interface involves a large part of the "toxin-like" sequences of SARS-CoV and SARS-CoV-2 Spike glycoproteins and toxin binding site of human α7 nAChR. Our findings provide further support to the hypothesis about the protective role of nicotine and other cholinergic agonists. The potential therapeutic role of CR3022 and other similar monoclonal antibodies with increased affinity for SARS-CoV-2 Spike glycoprotein against the clinical effects originating from the dysregulated cholinergic pathway should be further explored.

Indexed as

Epitopesalpha7 Nicotinic Acetylcholine ReceptorAmino Acid SequenceAntibodies, MonoclonalAntibodies, ViralBinding Sites, AntibodyCOVID-19HumansModels, MolecularNicotineNicotinic AgonistsNon-Neuronal Cholinergic SystemPandemicsProtective FactorsProtein ConformationSARS-CoV-2alpha7 Nicotinic Acetylcholine ReceptorAntibodies, MonoclonalAntibodies, ViralEpitopesNicotineNicotinic AgonistsSnake VenomsSpike Glycoprotein, Coronavirusspike glycoprotein, SARS-CoVCOVID-19CR3022Cryptic epitopeMolecular modelingnAChRsSARS-CoV-2Spike glycoprotein

Identifiers

PMID33503469
PMCPMC7830272
OpenAlexW3125747695

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.